UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 26.

Matter-Walstra, K W; Achermann, R; Rapold, R; Klingbiel, D; Bordoni, A; Dehler, S; Konzelmann, I; Mousavi, M; Clough-Gorr, K M; Szucs, T; Schwenkglenks, M; Pestalozzi, B C (2017). Days spent in acute care hospitals at the end of life of cancer patients in four Swiss cantons: a retrospective database study (SAKK 89/09). European Journal of Cancer Care, 26(4):e12453.

Matter-Walstra, Klazien; Braun, R; Kolb, C; Ademi, Z; Dummer, R; Pestalozzi, B C; Schwenkglenks, Matthias (2016). Treatment specific utility-weightings are needed for cost-utility analysis in metastatic melanoma: reply from the authors. British Journal of Dermatology, 174(2):463.

Matter-Walstra, K; Braun, R; Kolb, C; Ademi, Z; Dummer, R; Pestalozzi, B C; Schwenkglenks, M (2015). A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-mutated melanoma in the Swiss setting. British Journal of Dermatology, 173(6):1462-1470.

Pircher, M; Winder, T; Pestalozzi, B C; Petrausch, U (2015). Immuntherapien – eine neue tragende Säule der Onkologie. PharmaJournal, 20:5-11.

Eiermann, W; Bergh, J; Cardoso, F; Conte, P; Crown, J; Curtin, N J; Gligorov, J; Gusterson, B; Joensuu, H; Linderholm, B K; Martin, M; Penault-Llorca, F; Pestalozzi, B C; Razis, E; Sotiriou, C; Tjulandin, S; Viale, G (2012). Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design. Breast, 21(1):20-26.

Samaras, P; Breitenstein, S; Haile, S R; Stenner-Liewen, F; Heinrich, S; Feilchenfeldt, J; Renner, C; Knuth, A; Pestalozzi, B C; Clavien, P A (2011). Selective intra-arterial chemotherapy with floxuridine as second- or third-line approach in patients with unresectable colorectal liver metastases. Annals of Surgical Oncology, 18(7):1924-1931.

Zardavas, D; Meisel, A; Samaras, P; Knuth, A; Renner, C; Pestalozzi, B C; Stenner-Liewen, F (2011). Temsirolimus is highly effective as third-line treatment in chromophobe renal cell cancer. Case Reports in Oncology, 4(1):16-18.

Riener, M O; Vogetseder, A; Pestalozzi, B C; Clavien, P A; Probst-Hensch, N; Kristiansen, G; Jochum, W (2010). Cell adhesion molecules P-cadherin and CD24 are markers for carcinoma and dysplasia in the biliary tract. Human Pathology, 41(11):1558-1565.

Misselwitz, B; Goede, J S; Pestalozzi, B C; Schanz, U; Seebach, J D (2010). Hyperlipidemic myeloma: review of 53 cases. Annals of Hematology, 89(6):569-577.

Samaras, P; Buset, E M; Siciliano, R D; Haile, S R; Petrausch, U; Mischo, A; Honegger, H; Pestalozzi, B C; Schanz, U; Stüssi, G; Stahel, R A; Knuth, A; Renner, C; Stenner-Liewen, F (2010). Equivalence of pegfilgrastim and filgrastim in lymphoma patients treated with BEAM followed by autologous stem cell transplantation. Oncology, 79(1-2):93-97.

Riener, M O; Fritzsche, F R; Soll, C; Pestalozzi, B C; Probst-Hensch, N M; Clavien, P A; Jochum, W; Soltermann, A; Moch, H; Kristiansen, G (2010). Expression of the extracellular matrix protein periostin in liver tumours and bile duct carcinomas. Histopathology, 56(5):600-606.

Probst-Hensch, N M; Steiner, J H B; Schraml, P; Varga, Z; Zürrer-Härdi, U; Storz, M; Korol, D; Fehr, M K; Fink, D; Pestalozzi, B C; Lütolf, U M; Theurillat, J P; Moch, H (2010). IGFBP2 and IGFBP3 protein expressions in human breast cancer: association with hormonal factors and obesity. Clinical Cancer Research, 16(3):1025-1032.

Matter-Walstra, K W; Dedes, K J; Schwenkglenks, M; Brauchli, P; Szucs, T D; Pestalozzi, B C (2010). Trastuzumab beyond progression: a cost-utility analysis. Annals of Oncology, 21(11):2161-2168.

Dedes, K J; Matter-Walstra, K; Schwenkglenks, M; Pestalozzi, B C; Fink, D; Brauchli, P; Szucs, T D (2009). Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation. European Journal of Cancer, 45(8):1397-1406.

Riener, M O; Stenner, F; Liewen, H; Soll, C; Breitenstein, S; Pestalozzi, B C; Samaras, P; Probst-Hensch, N M; Hellerbrand, C; Müllhaupt, B; Clavien, P A; Bahra, M; Neuhaus, P; Wild, P; Fritzsche, F; Moch, H; Jochum, W; Kristiansen, G (2009). Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. Hepatology, 49(5):1602 -1609.

Riener, M O; Fritzsche, F R; Clavien, P A; Pestalozzi, B C; Probst-Hensch, N; Jochum, W; Kristiansen, G (2009). IMP3 expression in lesions of the biliary tract: a marker for high-grade dysplasia and an independent prognostic factor in bile duct carcinomas. Human Pathology, 40(10):1377-1383.

Pestalozzi, B C; et al; Gelber, R D; Viale, G (2008). Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? results of the CNS substudy in the intergroup Phase III BIG 02-98 Trial. Annals of Oncology, 19(11):1837-1841.

Bernhard, J; Dietrich, D; Scheithauer, W; Gerber, D; Bodoky, G; Ruhstaller, T; Glimelius, B; Bajetta, E; Schüller, J; Saletti, P; Bauer, J; Figer, A; Pestalozzi, B C; Köhne, C H; Mingrone, W; Stemmer, S M; Tàmas, K; Kornek, G V; Koeberle, D; Herrmann, R (2008). Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial - SAKK 44/00-CECOG/PAN.1.3.001. Journal of Clinical Oncology, 26(22):3695-3701.

Strobel, K; Heinrich, S; Bhure, U; Soyka, J; Veit-Haibach, P; Pestalozzi, B C; Clavien, P A; Hany, T F (2008). Contrast-enhanced 18F-FDG PET/CT: 1-stop-shop imaging for assessing the resectability of pancreatic cancer. Journal of Nuclear Medicine, 49(9):1408-1413.

Samaras, P; Pfammatter, T; Pestalozzi, B C (2008). Hemorrhage associated with hepatic artery pseudoaneurysms after regional chemotherapy with floxuridine: case report. International Seminars in Surgical Oncology, 5:17:1-5.

Pestalozzi, B C; Gruttadauria, S; Clavien, P A (2008). Hepatic arterial infusion: the beginning of the combination era. Journal of Clinical Oncology, 26(13):2231-2232.

Samaras, P; Dold, S; Braun, J; Kestenholz, P; Breitenstein, S; Imhof, A; Renner, C; Stenner-Liewen, F; Pestalozzi, B C (2008). Infectious port complications are more frequent in younger patients with hematologic malignancies than in solid tumor patients. Oncology, 74(3-4):237-244.

Heinrich, S; Schäfer, M; Weber, A; Hany, T F; Bhure, U; Pestalozzi, B C; Clavien, P A (2008). Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial. Annals of Surgery, 248(6):1014-1022.

Heinrich, S; Pestalozzi, B C; Schäfer, M; Weber, A; Bauerfeind, P; Knuth, A; Clavien, P A (2008). Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head. Journal of Clinical Oncology, 26(15):2526-2531.

Rentsch, K M; Schwendener, R; Pestalozzi, B C; Sauter, C; Wunderli-Allenspach, H; Hänseler, E (1998). Pharmacokinetic studies of mitoxantrone and one of its metabolites in serum and urine in patients with advanced breast cancer. European Journal of Clinical Pharmacology, 54(1):83-89.

Pestalozzi, B C; Vass, A; Adam, H; Horber, D H; Schwendener, R; Sauter, C (1995). Phase II study of liposome-complexed mitoxantrone in patients with advanced breast cancer. European Journal of Cancer, 31A(6):1024.

This list was generated on Fri Jul 28 15:54:12 2017 CEST.